CX3CL1 and Parkinsonism: For example, in Parkinson’s pathology, the soluble form of CX3CL1 has been shown to have a neuroprotective effect against α-synuclein-mediated injury by reducing dopaminergic neuron loss by 40-50%; differently, the membrane form has not a similar effect.